# Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)

> **NCT07507825** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First People's Hospital of Hangzhou** · enrollment: 61 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Intervention for Venetoclax
- **DRUG:** Intervention for Homoharringtonine
- **DRUG:** Intervention for Azacitidine
- **DRUG:** Intervention for G-CSF

## Key facts

- **NCT ID:** NCT07507825
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07507825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07507825, "Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07507825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*